Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

AGN-151586

7 clinical trials

2 indications

Indication
Frown Lines
Indication
Glabellar Lines
Clinical trial
A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines in Toxin-Naïve Subjects
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled Study of AGN-151586 in the Treatment of Japanese Subjects With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2024-04-03
Clinical trial
A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of AGN-151586 for the Treatment of Moderate to Severe Glabellar Lines
Status: Recruiting, Estimated PCD: 2025-03-22
Clinical trial
A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
A Phase 1 Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) in Subjects for Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2023-05-30
Clinical trial
A Phase 3, Multicenter, Open-label Study to Evaluate the Safety of AGN-151586 for the Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2023-06-26
Clinical trial
A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2020-09-09